What have we learned about antinociceptive effect of botulinum toxin type A from mirror-image pain models?

Višnja Drinovac Vlah; Lidija Bach-Rojecky

doi:10.1016/j.toxicon.2020.07.014

What have we learned about antinociceptive effect of botulinum toxin type A from mirror-image pain models?

Toxicon. 2020 Oct 15:185:164-173. doi: 10.1016/j.toxicon.2020.07.014. Epub 2020 Jul 19.

Authors

Višnja Drinovac Vlah¹, Lidija Bach-Rojecky²

Affiliations

¹ Department of Pharmacology, University of Zagreb Faculty of Pharmacy and Biochemistry, Domagojeva 2, 10000, Zagreb, Croatia. Electronic address: vdrinovac@pharma.hr.
² Department of Pharmacology, University of Zagreb Faculty of Pharmacy and Biochemistry, Domagojeva 2, 10000, Zagreb, Croatia. Electronic address: lbach@pharma.hr.

PMID: 32698026
DOI: 10.1016/j.toxicon.2020.07.014

Abstract

Mirror pain represents pain with complex pathophysiological background experienced at both sides of the body, usually after unilateral injury. Although observed almost 10 years ago, the phenomenon of bilateral antinociceptive effect of botulinum toxin type A (BoNT/A) following its unilateral administration in experimental mirror-image pain (MP) models remains challenging and intriguing task to explain. Data generated so far using MP models and mechanisms behind this unique feature of BoNT/A might influence the overall understanding of its mechanism of antinociceptive action. Here we review the effects contributing to BoNT/A's bilateral antinociceptive action observed in experimental MP models.

Keywords: Bilateral antinociceptive effect; Botulinum neurotoxin type A; Mirror pain; Synaptosomal-associated protein of 25 kDa.

Publication types

Review

MeSH terms

Analgesics / therapeutic use*
Animals
Botulinum Toxins, Type A / therapeutic use*
Humans
Pain / drug therapy*

Substances

Analgesics
Botulinum Toxins, Type A
incobotulinumtoxinA